ProFactor Pharma LTD is a UK-based biotech company founded in 2009 by Professor J H McVey and Dr Ian Garner, who have dedicated over 25 years to studying recombinant human Factor VIII (rhFVIII). Despite the unfortunate loss of Ian and team member Hugh Ilyine, ProFactor Pharma has persevered and made significant strides in the field. The team, now including experienced pharmaceutical executives, has partnered with Bio Farma Persero from Indonesia to collaborate on the development, clinical trials, and commercialization of their innovative recombinant Factor VIII.

This essential protein, despite its complexities and instability, demands specific expertise in handling and production, skills that ProFactor Pharma possesses. ProFactor Pharma has successfully developed a patent-protected, cost-effective production process using a Good Manufacturing Practice (GMP) compatible cell-line. Optimized and manufactured for toxicology studies in 2021, their final product is ready for clinical trials in 2024 in collaboration with Bio Farma.

With a strong technology foundation and a dedicated team, ProFactor Pharma is committed to advancing the treatment and management of hemophilia